

World Journal of *Critical Care Medicine*

World J Crit Care Med 2022 November 9; 11(6): 342-389



Contents

Bimonthly Volume 11 Number 6 November 9, 2022

MINIREVIEWS

- 342 Rationale for integration of palliative care in the medical intensive care: A narrative literature review
Gupta N, Gupta R, Gupta A
- 349 Current role of high dose vitamin C in sepsis management: A concise review
Juneja D, Nasa P, Jain R

ORIGINAL ARTICLE

Retrospective Study

- 364 Scoring systems in critically ill: Which one to use in cancer patients?
Beniwal A, Juneja D, Singh O, Goel A, Singh A, Beniwal HK

SYSTEMATIC REVIEWS

- 375 Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of the literature
Wajekar AS, Solanki SL, Patil VP

CORRECTION

- 387 Correction to "Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital"
Iglesias JJ, Vassallo AV

ABOUT COVER

Peer Reviewer of *World Journal of Critical Care Medicine*, Yin Ping Wong, FIAC, MD, Assistant Professor, Department of Pathology, Universiti Kebangsaan Malaysia, Cheras 56000, Kuala Lumpur, Malaysia.
ypwong@ppukm.ukm.edu.my

AIMS AND SCOPE

The primary aim of the *World Journal of Critical Care Medicine* (WJCCM, *World J Crit Care Med*) is to provide scholars and readers from various fields of critical care medicine with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJCCM mainly publishes articles reporting research results and findings obtained in the field of critical care medicine and covering a wide range of topics including acute kidney failure, acute respiratory distress syndrome and mechanical ventilation, application of bronchofiberscopy in critically ill patients, cardiopulmonary cerebral resuscitation, coagulant dysfunction, continuous renal replacement therapy, fluid resuscitation and tissue perfusion, hemodynamic monitoring and circulatory support, ICU management and treatment control, sedation and analgesia, severe infection, etc.

INDEXING/ABSTRACTING

The WJCCM is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yi-Xuan Cai, Production Department Director: Xiang Li, Editorial Office Director: Li-Li Wang.

NAME OF JOURNAL

World Journal of Critical Care Medicine

ISSN

ISSN 2220-3141 (online)

LAUNCH DATE

February 4, 2012

FREQUENCY

Bimonthly

EDITORS-IN-CHIEF

Hua-Dong Wang

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2220-3141/editorialboard.htm>

PUBLICATION DATE

November 9, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Correction to “Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital”

Jose I Iglesias, Andrew V Vassallo

Specialty type: Critical care medicine

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Ata F, Qatar; Aydin S, Turkey; Yu L, Singapore; Yu L, Singapore

Received: May 4, 2022

Peer-review started: May 4, 2022

First decision: June 16, 2022

Revised: June 23, 2022

Accepted: September 22, 2022

Article in press: September 22, 2022

Published online: November 9, 2022



Jose I Iglesias, Department of Critical Care, Community Medical Center, Toms River, NJ 08757, United States

Andrew V Vassallo, Department of Pharmacy, Community Medical Center, Toms River, NJ 08757, United States

Corresponding author: Jose I Iglesias, DO, FASN, Department of Critical Care, Community Medical Center, 99 W Rt 37, Toms River, NJ 08757, United States. jiglesias23@gmail.com

Abstract

Correction to: “Iglesias JI *et al.* Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. *World J Crit Care Med* 2021 Sep 9; 10(5): 244-259. DOI: 10.5492/wjccm.v10.i5.244. PMID: 34616660; PMCID: PMC8462025.” In this article, corrections were made to Tables.

Key Words: Corrections; COVID-19; Corticosteroids; Intensive care unit; Methylprednisolone; Tocilizumab; Anti-inflammatory

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This manuscript is an author's correction for “Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital.” *World J Crit Care Med* 2021 Sep 9; 10(5): 244-259. DOI: 10.5492/wjccm.v10.i5.244. PMID: 34616660; PMCID: PMC8462025.

Citation: Iglesias JI, Vassallo AV. Correction to “Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital”. *World J Crit Care Med* 2022; 11(6): 387-389

URL: <https://www.wjgnet.com/2220-3141/full/v11/i6/387.htm>

DOI: <https://dx.doi.org/10.5492/wjccm.v11.i6.387>

TO THE EDITOR

Correction to: Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad

Table 1 Coronavirus disease 2019 patients admitted to intensive care unit characteristics of survivors and non-survivors

	Non-survivor (n = 167)	Survivors (n = 94)	P value	OR	95%CI
Age	72 (63-82)	65.5 (51-74)	< 0.001		
Race (Caucasian)	125 (74.9)	57 (60.6)	0.016	1.9	1.12-3.3
BMI	29 (23.9, 34.7)	28.6 (24, 33)	0.49		
Sex (male)	102 (61)	56 (60)	0.81	1.065	0.63-1.78
Diabetes	60 (35)	24 (26)	0.08	1.63	0.93-2.8
CHF	24 (15)	10 (11)	0.38	1.42	0.64-3.1
CAD	45 (27)	20 (21)	0.30	1.36	0.74-2.48
COPD	38 (23)	23 (25)	0.75	0.9	0.5-1.64
CKD	25 (15)	13 (14)	0.8	1.09	0.53-2.26
HTN	100 (60)	45 (48)	0.061	1.62	0.97-2.70
AKI	87 (52)	30 (32)	0.002	2.3	1.21-2.5
Mechanical ventilation	134 (80)	44 (47)	< 0.001	4.6	2.64-8
Hemodialysis	29(18)	10 (11)	0.13	1.8	0.83-3.8
Neutrophils × 10 ⁹ /L	7.4 (5-11.79)	7.8 4.4-12.9	0.92		
Lymphocytes	0.7 (0.5, 1.2)	0.9 (0.6, 1.6)	0.011		
Neutrophil/lymphocyte	10 (6, 18.5)	7.54 4.3-14.2	0.017		
SCr (mg/dL)	1.2 (0.8-1.8)	1.1 (0.8, 0.8)	0.49		
Plts (× 10 ⁹ /L)	202 (166-268)	232 (155-301)	0.27		
Tbili (mg/dl)	0.5 (0.4, 0.8)	0.5 (0.4, 0.8)	0.65		
SOFA admit	4 (3-7)	4 (2, 6)	0.095		
PaO ₂ /FIO ₂	190 (76, 285)	232 (123, 307)	0.039		
PaO ₂	69 (55-86)	73 (59-96)	0.083		
FIO ₂	0.44 (0.24-1)	0.36 (0.21-0.97)	0.12		

OR: Odds ratio; CI: Confidence interval; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; CHF: Congestive heart failure; AKI: Acute kidney injury; HD: Hemodialysis; tBili: Total bilirubin; Plts: Platelets INR: International normalized ratio; PaO₂/FiO₂: Partial pressure of oxygen/inspired concentration of oxygen ratio; SOFA: Sequential Organ Failure Assessment; BMI: Body mass index; SCr: Serum creatinine.

L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. *World J Crit Care Med* 2021 Sep 9; 10(5): 244-259. DOI: 10.5492/wjccm.v10.i5.244. PMID: 34616660; PMCID: PMC8462025[1].

In the original manuscript, there are some errors in the table data presented, which need to be modified. The corrected tables are shown as **Table 1** (original Table 1) and **Table 2** (original Table 4). These errors do not change the ultimate results and conclusion of the paper but have been provided for clarification and overall accuracy.

Patient characteristics are described in **Table 1**. Univariate predictors of decreased survival included the need for mechanical ventilation, acute kidney injury, Caucasian race, older age, lower total lymphocyte count, higher neutrophil/Lymphocyte ratio, and a greater degree of respiratory failure manifested by a lower PaO₂/FIO₂ ratio. As anticipated non-survivors demonstrated a higher degree of elevated inflammatory and pro-thrombotic markers, D-Dimer at 24 h (**Table 2**, Original Table 4).

Table 2 Inflammatory markers in coronavirus disease 2019 survivors and non-survivors

	Non-survivors (n = 167)	Survivors (n = 94)	P value
IL-6 day 1 (pg/mL)	116 (33, 410)	72 (45, 210)	0.75
IL-6 day 2	470 (36, 1299)	153 (10, 280)	0.38
D-Dimer day 1 (ng/mL)	855 (522, 2434)	595 (337, 1349)	0.013
D-Dimer day 2	691 (436, 1743)	1040 (550, 3431)	0.11
CRP day 1 (mg/L)	125 (61, 179)	130 (89, 185)	0.55
CRP day 2	116 (82, 185)	119 (47, 175)	0.29
Ferritin day 1 (ng/mL)	869 (406, 1467)	995 (488, 1571)	0.35
Ferritin day 2	822 (447, 1432)	1053 (712, 2057)	0.05

IL-6: Interleukin 6, CRP: C-reactive protein.

FOOTNOTES

Author contributions: Iglesias JI did the formal analysis; Vassallo AV did the original draft editing and project administration; all authors participate in the manuscript conceptualization, methodology and original draft writing.

Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: United States

ORCID number: Jose I Iglesias [0000-0001-7851-0498](https://orcid.org/0000-0001-7851-0498).

S-Editor: Wu YXJ

L-Editor: A

P-Editor: Wu YXJ

REFERENCES

- Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. *World J Crit Care Med* 2021; **10**: 244-259 [PMID: [34616660](https://pubmed.ncbi.nlm.nih.gov/34616660/) DOI: [10.5492/wjccm.v10.i5.244](https://doi.org/10.5492/wjccm.v10.i5.244)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

